Clinical Data Trial miss doesn’t dent Biogen’s faith in Alzheimer’s drug PharmaphorumBiogen will advance its tau-targeting Alzheimer's disease drug diranersen into phase 3, even though it missed the main endpoint in a midstage trial.NeuroscienceRead full story pharminent May 14, 2026 (Last updated: May 21, 2026) Pharmaphorum Biogen will advance its tau-targeting Alzheimer’s disease drug diranersen into phase 3, even though it missed the main endpoint in a midstage trial. Neuroscience Read full story Post navigation Previous: REGENXBIO slumps after serious side effects mar Duchenne gene therapy resultsNext: ECO 2026: SURMOUNT-MAINTAIN proves tirzepatide sustains weight loss long term Related Stories Clinical Data Novartis hit as Lp(a) drug fails cardio outcomes trial pharminent September 7, 2026 Clinical Data Major trial of Roche Alzheimer’s drug kicks off in Europe pharminent September 7, 2026 Clinical Data AbbVie’s T cell engager delivers survival benefit in Phase 3 multiple myeloma study pharminent September 4, 2026